Request Demo
Last update 18 Oct 2025
LD-002
Last update 18 Oct 2025
Overview
Basic Info
Drug Type Biological products |
Synonyms LD 002, LD-002, LD002 |
Target |
Action inhibitors |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with LD-002CTR20220532
一项在晚期/转移性恶性实体瘤或非霍奇金淋巴瘤受试者中评价LD002注射液单药治疗的安全性、耐受性、初步有效性及药代动力学特征的多中心Ia期临床研究
[Translation] A multicenter Phase Ia clinical study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetic characteristics of LD002 injection monotherapy in subjects with advanced/metastatic malignant solid tumors or non-Hodgkin's lymphoma
100 Clinical Results associated with LD-002
Login to view more data
100 Translational Medicine associated with LD-002
Login to view more data
100 Patents (Medical) associated with LD-002
Login to view more data
2
Literatures (Medical) associated with LD-00201 Jan 2000Artificial cells, blood substitutes, and immobilization biotechnology
A Rapid Interferent-Free Assay for the Determination of LD-1 in Biological Samples
Article
Author: G G Guilbault ; S Kelly ; C K O'Sullivan ; C P Cronin
A highly specific enzyme linked immunosorbent assay (ELISA) for the detection of lactate dehydrogenase-1 (LD-1) has been developed. A competition assay is described with polyclonal antibody to LD-1 passively adsorbed on an ELISA 96-well plate, with non-labelled and labelled LD-1 antigen competing. The LD-1 antigen is conjugated to alkaline phosphatase (ALP) using the one step glutaraldehyde method. A linear range of 10-4000 U/L was obtained, and cross-reactivity was only observed with LD-2. It was possible to eliminate this cross-reactivity by carrying out the final incubation step at 65 degrees C. The developed assay was applied to the analysis of spiked serum and plasma samples and the recoveries obtained were acceptable.
01 Nov 1990Clinical chemistryQ1 · MEDICINE
Inhibition of lactate dehydrogenase isoenzymes by sodium perchlorate evaluated
Q1 · MEDICINE
Article
Author: Sanders, G T ; van der Neut, E ; van Straalen, J P
Abstract:
We evaluated a method of measuring lactate dehydrogenase isoenzyme 1 (LD-1) selectively (Clin Chem 1987;33:991-2), in which all other LD isoenzymes were inhibited by adding sodium perchlorate to the reaction medium to a final concentration of 0.825 mol/L. In this study we used the different isoenzymes purified from human autopsy tissue and found that the originally published amount of inhibitor (a) increased the original LD-1 activity and (b) did not eliminate all enzyme activity of LD-2 and LD-3. Interference by LD-2 was further demonstrated. Thus we conclude that this method cannot be used for the selective determination of LD-1 because its results do not accurately reflect the original LD-1 activity.
100 Deals associated with LD-002
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Liver Cancer | Phase 1 | China | 09 Mar 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 09 Mar 2022 | |
| Ovarian Cancer | Phase 1 | China | 09 Mar 2022 | |
| Recurrent Indolent Non-Hodgkin Lymphoma | Phase 1 | China | 09 Mar 2022 | |
| Refractory Indolent Non-Hodgkin Lymphoma | Phase 1 | China | 09 Mar 2022 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | China | 09 Mar 2022 | |
| Stomach Cancer | Phase 1 | China | 09 Mar 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free